Evidence-based management of non-alcoholic fatty liver disease

Abstract

Non-alcoholic fatty liver disease (NAFLD)it is the commonest cause of chronic liver disease in developed countries and is rapidly increasing in the Asia-Pacific region. NAFLD has important long term health implications. There is increased overall mortality most commonly from cardiovascular disease, and also increased liver-related mortality. Treatment options available for NAFLD include general measures at managing obesity and correcting the metabolic syndrome and liver-directed therapies aimed at reducing the liver inflammation and hepatocellular injury. This article reviews the current evidence based management of NAFLD and associated metabolic comorbidities.